second-line angiogenesis inhibition in metastatic renal cell carcinoma
Published 10 years ago • 289 plays • Length 8:31Download video MP4
Download video MP3
Similar videos
-
6:23
second-line treatment of metastatic renal cell carcinoma
-
7:06
pd-1 inhibition in metastatic renal cell carcinoma
-
11:26
axis trial: second-line axitinib versus sorafenib in metastatic renal cell carcinoma
-
7:09
second-line treatment selection in renal cell carcinoma
-
4:28
metastatic renal cell carcinoma: lenvatinib phase ii data
-
7:07
selecting second-line agents in renal cell carcinoma
-
2:16
second-line therapy for metastatic renal cell cancer
-
0:55
the emerging continuum of care in metastatic kidney cancer in the second-line and beyond
-
5:29
first- and second-line treatments for locally advanced renal cell carcinoma
-
12:21
intorsect trial: second-line temsirolimus versus sorafenib in renal cell carcinoma
-
4:16
metastatic rcc: decision trees for second-line therapy
-
8:43
optimizing the upfront treatment of metastatic renal cell carcinoma
-
5:36
sequencing metastatic renal cell carcinoma treatments
-
3:36
first-line treatment of poor-risk metastatic renal cell carcinoma
-
12:49
the tivo-3 study of tivozanib in metastatic renal cell carcinoma
-
2:22
promising second-line therapies for mrcc
-
2:31
toni choueiri, md, describes treatment strategies for 2nd line renal cell carcinoma
-
0:50
dr. viktor grünwald on dovitinib versus sorafenib in metastatic renal cell carcinoma
-
6:43
metastatic renal cell carcinoma: emerging data, future directions